Anti-Cancer Agents in Medicinal Chemistry
Title:Meet Our Editorial Board Member
Volume: 17 Issue: 9
Author(s): Cinzia Lanzi
Affiliation:
Export Options
About this article
Cite this article as:
Lanzi Cinzia , Meet Our Editorial Board Member, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (9) . https://dx.doi.org/10.2174/187152061709170912113321
DOI https://dx.doi.org/10.2174/187152061709170912113321 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
27
2
1
1
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Use of Chemokines
Current Pharmaceutical Design Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design An Overview of Labeled Porphyrin Molecules in Medical Imaging
Recent Patents and Topics on Imaging (Discontinued) Synthesis and Altered Biodistribution of 99mTc Labeled Vincristine in Animal Model
Current Medical Imaging Recent Advances in Metabolic Profiling and Imaging of Prostate Cancer
Current Metabolomics Deoxypodophyllotoxin Isolated from Juniperus communis Induces Apoptosis in Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Current Genomics Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC.
Reviews on Recent Clinical Trials Biomarkers, Critical Disease Pathways, Drug Targets, and Alternative Medicine in Male Breast Cancer
Current Drug Targets <sup>177</sup>Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay
Current Radiopharmaceuticals Unequivocal Role of Pyrazine Ring in Medicinally Important Compounds: A Review
Mini-Reviews in Medicinal Chemistry Genetically Modified Cellular Vaccines for Therapy of Human Papilloma Virus Type 16 (HPV 16)-Associated Tumours
Current Cancer Drug Targets PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Magnetically Responsive Paclitaxel-Loaded Biodegradable Nanoparticles for Treatment of Vascular Disease: Preparation, Characterization and In Vitro Evaluation of Anti-Proliferative Potential
Current Drug Delivery The Role of Shcbp1 in Signaling and Disease
Current Cancer Drug Targets Editorial [Hot Topic:New Research Tolls for Antique Pediatric Tumors:The Dilemma of Transposing Drug-Resistance (Guest Editor: E.T. Valera)]
Current Pharmaceutical Biotechnology Novel Drugs for Neuroblastoma
Drug Design Reviews - Online (Discontinued) Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine